Herbal medicine in the treatment of liver diseases

被引:254
作者
Stickel, F.
Schuppan, D.
机构
[1] Univ Bern, Inst Clin Pharmacol, CH-3010 Bern, Switzerland
[2] Harvard Univ, Sch Med, Beth Israel Med Ctr, Div Gastroenterol & Hepatol, Boston, MA 02115 USA
关键词
alternative medicine; antifibrotic therapy; glycirrhizin; hepatotoxicity; herbal medicine; liver disease; silymarin;
D O I
10.1016/j.dld.2006.11.004
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Herbal drugs have become increasingly popular and their use is widespread. Licensing regulations and pharmacovigilance regarding herbal products are still incomplete and clearcut proof of their efficacy in liver diseases is sparse. Nevertheless, a number of herbals show promising activity including silymarin for antifibrotic treatment, phyllantus amarus in chronic hepatitis 13, glycyrrhizin to treat chronic viral hepatitis, and a number of herbal combinations from China and Japan that deserve testing in appropriate studies. Apart from therapeutic properties, reports are accumulating about liver injury after the intake of herbals, including those advertised for liver diseases. Acute and/or chronic liver damage occurred after ingestion of some Chinese herbs, herbals that contain pyrrolizidine alkaloids, germander, greater celandine, kava, atractylis gummifera, callilepsis laureola, senna alkaloids, chaparral and many others. Since the evidence supporting the use of botanicals to treat chronic liver diseases is insufficient and only few of them are well standardised and free of potential serious side effects, most of these medications are not recommended outside clinical trials. Particularly with regard to the latter, adequately powered randomised-controlled clinical trials with well-selected end points are needed to assess the role of herbal therapy for liver diseases. (c) 2006 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:293 / 304
页数:12
相关论文
共 142 条
[1]
Abe Y, 1994, Nihon Rinsho, V52, P1817
[2]
ACHARYA SK, 1993, INDIAN J MED RES-B, V98, P69
[3]
Pennyroyal toxicity: Measurement of toxic metabolite levels in two cases and review of the literature [J].
Anderson, IB ;
Mullen, WH ;
Meeker, JE ;
KhojastehBakht, SC ;
Oishi, S ;
Nelson, SD ;
Blanc, PD .
ANNALS OF INTERNAL MEDICINE, 1996, 124 (08) :726-+
[4]
Silymarin in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid [J].
Angulo, P ;
Patel, T ;
Jorgensen, RA ;
Therneau, TM ;
Lindor, KD .
HEPATOLOGY, 2000, 32 (05) :897-900
[5]
[Anonymous], CHINESE J INTEGR TRA
[6]
[Anonymous], CHIN J GASTROENTEROL
[7]
Arase Y, 1997, CANCER, V79, P1494, DOI 10.1002/(SICI)1097-0142(19970415)79:8<1494::AID-CNCR8>3.0.CO
[8]
2-B
[9]
The irony of herbal hepatitis - Ma-Huang-induced hepatotoxicity associated with compound heterozygosity for hereditary hemochromatosis [J].
Bajaj, J ;
Knox, JF ;
Komorowski, R ;
Saeian, K .
DIGESTIVE DISEASES AND SCIENCES, 2003, 48 (10) :1925-1928
[10]
BAOEN W, 1999, COMPLEMENTARY ALTERN, P63